Forgot Password?
Return to Course Listing

CME: Glaucoma: therapeutic updates, best practices, and barriers to effective care


Activity Description / Statement of Need:

In this online, self-learning activity:

Glaucoma, a heterogeneous disease leading to progressive damage to the optic nerve, causes irreversible vision loss and affects approximately 64 million people worldwide.The prevalence of glaucoma is increasing, and more than 100 million people will have glaucoma by 2040.Approximately half of all individuals with glaucoma are unaware of their condition due to the asymptomatic nature of the disease. Although the incidence of glaucoma-related blindness has decreased over the last 20 years thanks to effective management strategies, 13% to 40% of people with glaucoma still develop unilateral or bilateral blindness, typically at a rate of 1.1% per year.

Target Audience:

The following healthcare professionals: ophthalmologists; physician assistants, nurse practitioners, nurses, and pharmacists with an interest in ophthalmology or diseases affecting the eye; and any other healthcare professionals with an interest in or who clinically encounter patients with glaucoma.

This program is supported by an educational grant from Bausch & Lomb.

Release Date: April 30, 2018 -- Expiration Date: April 30, 2020

Faculty: Robert Chang, MD


Monitoring intraocular pressure (IOP) and optimizing targets.

  • Diurnal IOP measurements
  • Advances toward 24-hour measurements
  • Considerations for IOP targets
    • Importance of visual and structural tests
    • Comorbidities
    • When are aggressive targets appropriate?

Current and emerging treatment options for glaucoma.

  • First-line therapies
    • When are prostaglandins not the first choice?
    • Selective laser trabeculotomy as a first-line option
    • Adjunctive therapies with prostaglandin analogues
    • Nitric oxide-delivering prostaglandin analogues
    • Fixed-combination drugs vs. polypharmacy
    • Drugs in clinical development
      • Rho kinase inhibitors
      • Adenosine A1 agonists
      • Barriers to care
      • Patient case(s)

Learning Objectives

By the end of the session the participant will be able to:

  • Individualize intraocular pressure targets based on known risk factors and patient-specific characteristics, and optimize assessment of intraocular pressure profiles to readily identify peaks and fluctuations
  • Identify first-line pharmacotherapies, laser therapies, and glaucoma implants for lowering intraocular pressure, and select appropriate monotherapies and combination therapies for patients
  • Discuss present and emerging pharmacotherapies currently in clinical development and their mechanisms of action, and apply those therapies to patient cases
  • Describe barriers to care in the treatment of patients with glaucoma and what clinicians may do to aide patients in circumventing them



Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

Faculty Disclosure: Dr. Chang, MD, Assistant Professor of Ophthalmology at the Stanford University Medical Center, Stanford, CA, is a Consultant  for Alcon (Novartis), Iridex, Aerie, Allergan,  and Santen; and has received grant support from Santen and Carl Zeiss Meditec.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP has no relevant conflicts of interest to disclose.

Commercial Support Disclosure: This program is supported by an educational grant from Bausch & Lomb.


  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

Additional Courses That Are Related To This Activity

Ocular surface disease (OSD): diagnostic, management, and clinical considerations in dry eye

Dry Eye Disease: Therapeutic Updates and Optimizing Treatment

Glaucoma: Updates from the AAO 2019 Annual Meeting

Glaucoma: Optimizing pharmacotherapeutic management strategies